.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Bitte aktivieren Sie Javascript um alle Funktionen nutzen zu können und ihre Nutzererfahrung zu verbessern.

Prof. Dr. Britta Eiz-Vesper

Hannover/ DE

Institut für Transfusionsmedizin und Transplantat Engineering

Vorsitz

21.09.2023
10:30 – 12:00
Plenarsitzung
Immunotherapy: Primary T cells
MOA 04+05

Weitere Beteiligungen

21.09.2023
08:54 – 09:06 10 Min. 2 Min.
Freier Vortrag
VS-10-3
Vitamin C conditioning creates CAR-T cells with superior cytotoxic capacity and metabolic fitness to combat the immunosuppressive tumor micromilieu
Immunotherapy
21.09.2023
09:30 – 09:38 7 Min. 1 Min.
Freier Vortrag
VS-10-7
Overcoming immune escape in EBV-associated PTLD by understanding the two levels of immunosuppression: the tumor microenvironment and iatrogenic immunosuppression
Immunotherapy
21.09.2023
09:38 – 09:48 8 Min. 2 Min.
Freier Vortrag
VS-10-8
Discovery of the human cytomegalovirus-specific peptide repertoire naturally processed and presented by infected human antigen presenting cells
Immunotherapy
22.09.2023
13:30 – 13:40 8 Min. 2 Min.
Freier Vortrag (Reinhold-Eckstein-Investigator-Award)
VS-22-1
Engineered T cells selectively depleting alloreactive B cells and resisting immunosuppressive treatment as tool to combat AMR following solid organ transplantation
Immunotherapy
22.09.2023
14:00 – 14:10 8 Min. 2 Min.
Freier Vortrag
VS-22-4
Next generation LMP2A-targeting TCR-recombinant T-Cells with inducible expression of Il-18 as promising tool to treat various EBV-associated malignancies
Immunotherapy
22.09.2023
14:10 – 14:20 8 Min. 2 Min.
Freier Vortrag
VS-22-5
4^th generation CAR-T cells with inducible cytokine expression targeting CD176 to overcome the immunosuppressive tumor milieu in lung cancer
Immunotherapy